628279-02-7 Usage
Uses
Used in Pharmaceutical Industry:
N-[4-(1-Allyl-3-butyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-ylmethyl)phenyl]acetamide is used as a key intermediate for the preparation of amide-substituted xanthine derivatives. These derivatives act as phosphoenolpyruvate carboxykinase (PEPCK) inhibitors, which play a crucial role in modulating gluconeogenesis. By inhibiting PEPCK, these compounds can help regulate blood glucose levels and are, therefore, valuable in the development of treatments for type 2 diabetes.
Check Digit Verification of cas no
The CAS Registry Mumber 628279-02-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,2,8,2,7 and 9 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 628279-02:
(8*6)+(7*2)+(6*8)+(5*2)+(4*7)+(3*9)+(2*0)+(1*2)=177
177 % 10 = 7
So 628279-02-7 is a valid CAS Registry Number.
628279-02-7Relevant academic research and scientific papers
AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY
-
, (2012/04/23)
The present invention is a 1,3,8 substituted xanthine derivative of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined in the specification. Compounds of formula (I) and pharmaceutically acceptable salts or prodrugs thereof show activity as modulators of gluconeogenesis.
Modified 3-alkyl-1,8-dibenzylxanthines as GTP-competitive inhibitors of phosphoenolpyruvate carboxykinase
Foley, Louise H.,Wang, Ping,Dunten, Pete,Ramsey, Gwendolyn,Gubler, Mary-Lou,Wertheimer, Stanley J.
, p. 3607 - 3610 (2007/10/03)
The first non-substrate like inhibitors of human cytosolic phosphoenolpyruvate carboxykinase (PEPCK) competitive with GTP are reported. An effort to discover orally active compounds that improve glucose homeostasis in Type 2 diabetics by reversibly inhibi
